42 Results for "

LDL-C

" in MedChemExpress (MCE) Product Catalog:
Products (42)

42 Results for "LDL-C" in MCE Product Catalog:

16
Pitavastatin
Pitavastatin
0 Images
16 Publications Verification
Cat. No.: HY-B0144A
CAS No.: 147511-69-1
Synonyms: NK-104
Target:  

HMG-CoA Reductase (HMGCR) Autophagy Mitophagy Apoptosis

Research Areas:  

Cardiovascular Disease Neurological Disease Metabolic Disease Cancer

Pitavastatin (NK-104) is a potent hydroxymethylglutaryl-CoA (HMG-CoA) reductase inhibitor. Pitavastatin inhibits cholesterol synthesis from acetic acid with an IC50 of 5.8 nM in HepG2 cells. Pitavastatin is an efficient hepatocyte low-density lipoprotein-cholesterol (LDL-C) receptor inducer. Pitavastatin also possesses anti-atherosclerotic, anti-asthmatic, anti-osteoarthritis, antineoplastic, neuroprotective, hepatoprotective and reno-protective effects .
loading...
    loading...
View All Sizes
16
Pitavastatin Calcium
Pitavastatin Calcium
0 Images
16 Publications Verification
Cat. No.: HY-B0144
CAS No.: 147526-32-7
Synonyms: NK-104 hemicalcium; Pitavastatin hemicalcium
Target:  

HMG-CoA Reductase (HMGCR) Autophagy Mitophagy Apoptosis

Research Areas:  

Cardiovascular Disease Neurological Disease Metabolic Disease Cancer

Pitavastatin Calcium (NK-104 hemicalcium) is a potent hydroxymethylglutaryl-CoA (HMG-CoA) reductase inhibitor. Pitavastatin Calcium (NK-104 hemicalcium) inhibits cholesterol synthesis from acetic acid with an IC50 of 5.8 nM in HepG2 cells. Pitavastatin Calcium is an efficient hepatocyte low-density lipoprotein-cholesterol (LDL-C) receptor inducer. Pitavastatin Calcium also possesses anti-atherosclerotic, anti-asthmatic, anti-osteoarthritis, antineoplastic, neuroprotective, hepatoprotective and reno-protective effects .
loading...
    loading...
View All Sizes
1
Alirocumab
Alirocumab
0 Images
1 Cited Publications
Cat. No.: HY-P9928
CAS No.: 1245916-14-6
Synonyms: REGN727; SAR 236553
Target:  

PCSK9 NOD-like Receptor (NLR) Keap1-Nrf2 HMG Family NF-κB CX3CR1

Research Areas:  

Cardiovascular Disease Inflammation/Immunology

Alirocumab is an anti-PCSK9 human monoclonal antibody. Alirocumab inhibits PCSK9. Alirocumab reduces NLRP3 inflammasome, regulates Nrf2/HO-1, HMGB1/NF-κB and Fractalkine/CX3CR1. Alirocumab increases the ability of the liver to bind LDL-cholesterol (LDL-C) and reduces levels of LDL-C in blood. Alirocumab improves atherosclerosis and inflammation .
loading...
    loading...
View All Sizes
1
Obicetrapib
Obicetrapib
0 Images
1 Cited Publications
Cat. No.: HY-18778
CAS No.: 866399-87-3
Synonyms: TA-8995; DEZ-001; AMG-899
Target:  

CETP Apolipoprotein LPL Receptor LDLR

Research Areas:  

Cardiovascular Disease

Obicetrapib (TA-8995; DEZ-001) is an orally active cholesteryl ester transfer protein (CETP) inhibitor. Obicetrapib potently reduces atherogenic lipoproteins (such as LDL-C, ApoB, Lp (a)) and increases HDL-C. Obicetrapib can be used for the research of dyslipidemia and atherosclerotic cardiovascular disease (ASCVD) .
loading...
    loading...
View All Sizes
1
GalNAc unconjugated/naked Inclisiran
GalNAc unconjugated/naked Inclisiran
0 Images
1 Cited Publications
Cat. No.: HY-150223
Purity:  92.48%
Target:  

PCSK9 Small Interfering RNA (siRNA)

Research Areas:  

Cardiovascular Disease

GalNAc unconjugated/naked Inclisiran is a double-stranded small interfering RNA molecule that targets hepatic PCSK9 production to reduce LDL-C levels. GalNAc unconjugated/naked Inclisiran can be used in the research of cardiovascular diseases and hypercholesterolemia .
loading...
    loading...
View All Sizes
1
Alirocumab (anti-PCSK9)
Alirocumab (anti-PCSK9)
0 Images
1 Cited Publications
Cat. No.: HY-P9928A
CAS No.: 1245916-14-6
Synonyms: REGN 727(anti-PCSK9); SAR 236553(anti-PCSK9)

Target:  

PCSK9 NOD-like Receptor (NLR) Keap1-Nrf2 HMG Family NF-κB CX3CR1

Research Areas:  

Cardiovascular Disease Cancer

Alirocumab (anti-PCSK9) is an anti-PCSK9 human monoclonal antibody. Alirocumab (anti-PCSK9) inhibits PCSK9. Alirocumab (anti-PCSK9) reduces NLRP3 inflammasome, regulates Nrf2/HO-1, HMGB1/NF-κB and Fractalkine/CX3CR1. Alirocumab (anti-PCSK9) increases the ability of the liver to bind LDL-cholesterol (LDL-C) and reduces levels of LDL-C in blood. Alirocumab (anti-PCSK9) improves atherosclerosis and inflammation .
loading...
    loading...
View All Sizes
Rebaudioside A
Rebaudioside A
0 Images
Cat. No.: HY-N0466
CAS No.: 58543-16-1
Category:  

Plants Endogenous metabolite Sweeteners Food Research 500 - Internal Server Error | MedChemExpress

Oops!

Sorry, Something went wrong on our server.
Our team has been notified and is working to fix the issue.